Recent Analysts’ Ratings Changes for Wave Life Sciences (WVE)

A number of research firms have changed their ratings and price targets for Wave Life Sciences (NASDAQ: WVE):

  • 8/8/2019 – Wave Life Sciences was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 8/8/2019 – Wave Life Sciences was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 8/3/2019 – Wave Life Sciences was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “WAVE Life Sciences Pte. Ltd. is a preclinical biopharmaceutical company. It designs, develops and commercializes nucleic acid therapeutic candidates for Huntington’s disease, Duchenne muscular dystrophy and inflammatory bowel disease. Huntington’s disease, the Company has programs targeting HTT SNP-1 and HTT SNP-2; DMD, targeting Exon 51 and in IBD, it is targeting SMAD7. The Company has late-stage discovery programs in epidermolysis bullosa simplex, in which it is targeting KRT14 SNP-1 and KRT14 SNP-2 and in DMD, it is focused on an additional DMD target, Activin Receptor type IIb. WAVE Life Sciences Pte. Ltd. is based in Singapore. “
  • 7/31/2019 – Wave Life Sciences had its “buy” rating reaffirmed by analysts at HC Wainwright. They wrote, “Our $33 target is based on a risk-adjusted, sum-of-the-parts DCF analysis: beta of 1.16, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 8.0%, and tax rate of 15% beginning in FY 2030, and is now 100% leveraged to the company’s CNS portfolio. Risks to our target include: commercial, reimbursement, regulatory, along with clinical and manufacturing. WAVE Life Sciences Ltd.””
  • 7/30/2019 – Wave Life Sciences had its “hold” rating reaffirmed by analysts at Cowen Inc.
  • 7/22/2019 – Wave Life Sciences had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $65.00 price target on the stock.
  • 7/15/2019 – Wave Life Sciences is now covered by analysts at Cowen Inc. They set a “market perform” rating on the stock.
  • 7/13/2019 – Wave Life Sciences was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 6/29/2019 – Wave Life Sciences was given a new $65.00 price target on by analysts at Mizuho. They now have a “buy” rating on the stock.
  • 6/28/2019 – Wave Life Sciences was given a new $33.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 6/18/2019 – Wave Life Sciences was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.

Wave Life Sciences stock traded down $0.66 during trading hours on Thursday, hitting $20.34. The company had a trading volume of 194,800 shares, compared to its average volume of 384,760. The firm has a market capitalization of $719.89 million, a P/E ratio of -4.02 and a beta of 0.81. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.33 and a quick ratio of 2.33. The firm’s fifty day moving average is $23.34 and its 200-day moving average is $30.69. Wave Life Sciences Ltd has a fifty-two week low of $18.16 and a fifty-two week high of $56.00.

Wave Life Sciences (NASDAQ:WVE) last posted its quarterly earnings data on Monday, July 29th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.11) by ($0.11). Wave Life Sciences had a negative return on equity of 120.41% and a negative net margin of 861.41%. The firm had revenue of $7.63 million for the quarter, compared to the consensus estimate of $15.76 million. Analysts anticipate that Wave Life Sciences Ltd will post -5.38 earnings per share for the current year.



In other news, insider Michael A. Panzara sold 3,058 shares of the firm’s stock in a transaction dated Friday, July 5th. The shares were sold at an average price of $26.94, for a total value of $82,382.52. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 39.70% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. Voloridge Investment Management LLC purchased a new stake in shares of Wave Life Sciences during the 2nd quarter valued at $585,000. Nuveen Asset Management LLC purchased a new stake in shares of Wave Life Sciences during the 2nd quarter valued at $2,028,000. Morgan Stanley increased its position in shares of Wave Life Sciences by 140.6% during the 2nd quarter. Morgan Stanley now owns 18,692 shares of the company’s stock valued at $487,000 after purchasing an additional 10,922 shares during the last quarter. Bank of America Corp DE increased its position in shares of Wave Life Sciences by 16.9% during the 2nd quarter. Bank of America Corp DE now owns 32,310 shares of the company’s stock valued at $843,000 after purchasing an additional 4,682 shares during the last quarter. Finally, BlackRock Inc. increased its position in shares of Wave Life Sciences by 6.7% during the 2nd quarter. BlackRock Inc. now owns 1,811,996 shares of the company’s stock valued at $47,275,000 after purchasing an additional 113,292 shares during the last quarter. 86.28% of the stock is currently owned by institutional investors.

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Further Reading: Death Cross

Receive News & Ratings for Wave Life Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.